EMPIRE CONSULTING GROUP

Lobbying for AMGEN INC. · Healthcare/Biotechnology

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jan 19, 2026

Lobbying activity 1

Health Issues

Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.